Meropenem Navamedic (Meropenem Anhydrous)

Meropenem is a carbapenem antibiotic used to treat serious infections caused by resistant bacteria.

• Complicated intra‑abdominal infection: provides broad‑spectrum coverage to eradicate mixed aerobic and anaerobic organisms.
• Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: achieves rapid bacterial clearance in severe lung infections.
• Complicated urinary tract infection: eliminates resistant Gram‑negative pathogens causing pyelonephritis.
• Bacterial meningitis: penetrates the cerebrospinal fluid to treat life‑threatening central nervous system infections.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its structure confers resistance to most β‑lactamases, allowing activity against a wide range of Gram‑negative, Gram‑positive and anaerobic organisms. The drug is time‑dependent, requiring prolonged plasma concentrations above the minimum inhibitory concentration for optimal effect.

Meropenem may cause adverse reactions ranging from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: may be watery or loose.
• Headache: transient cranial discomfort.
• Elevated liver enzymes: mild hepatic enzyme rise.
• Rash: mild skin erythema.
• Phlebitis at infusion site: local irritation.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment.
• Anaphylaxis: severe allergic reaction requiring immediate treatment.
• Clostridioides difficile colitis: severe intestinal infection.
• Hemolytic anemia: destruction of red blood cells.
• Acute kidney injury: sudden loss of renal function.

When using Meropenem, clinicians should consider several safety precautions to minimize risks.

• Renal function: adjust dose in patients with impaired kidney function.
• Hypersensitivity: avoid in individuals with known allergy to β‑lactam antibiotics.
• Central nervous system: monitor for seizures, especially in those with pre‑existing CNS disorders.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Concomitant antibiotics: assess for additive toxicity when combined with other nephrotoxic or neurotoxic agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: may reduce serum valproate levels, risking seizure breakthrough.
• Probenecid: can increase meropenem plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: combined nephrotoxicity; monitor renal function.
• Loop diuretics: may enhance ototoxicity when used together.
• Anticoagulants (warfarin): possible alteration of INR; check coagulation parameters.
• Other β‑lactam antibiotics: additive risk of hypersensitivity reactions.